Topical formulations of the active ingredient, ketoprofen, are relevant across therapeutic domains involving localized musculoskeletal distress and inflammatory processes. Topical ketoprofen is commonly utilized to address symptoms of pain and inflammation in conditions such as minor trauma including sprains and bruising, tendonitis, and small-joint osteoarthritis.

Targeting Localized Pain in Acute Soft Tissue Injuries

The Cataplasma is commonly used across domains where additional symptomatic support is needed, and is relevant for easing localized pain and inflammation in conditions including acute strains and sprains. The medicine is relevant in clinical settings that involve acute or disruptive symptom patterns, and provides support that helps ease the overall symptom load.

Symptomatic Relief for Chronic Joint and Tendon Discomfort

The medication is commonly used across conditions characterized by periods of heightened symptoms, including certain manifestations of osteoarthritis and conditions like periarthritis and tenosynovitis. The patch is commonly used to help with symptom clusters that may become intense or disruptive. The Cataplasma provides supportive relief when symptoms interfere with routine activities, which may help ease the overall symptom load.

Quick Fact: Relief for Localized Symptoms
Primary Goal	Symptomatic management of local pain and swelling.
Key Scenarios	Acute injuries and chronic inflammatory conditions of soft tissues.
Patient Benefit	Provides support that helps ease the overall symptom load.

Eligibility Scope

The official eligibility profile for Ketoplus Cataplasma (Ketoprofen Topical) is defined by strict regulatory exclusions and use restrictions.

Classification	Population/Condition
Allowed	Adults (18 years and older) under standard labeled conditions.
Contraindicated	Women in the third trimester of pregnancy.
Contraindicated	Children and adolescents under 15 years of age.
Contraindicated	Patients with known hypersensitivity to Ketoprofen, other NSAIDs, or salicylates.
Contraindicated	Patients with a history of photoallergic reactions or allergic reactions to UV exposure.
Contraindicated	Application to pathological skin changes (e.g., eczema, open wounds, infected skin).
Contraindicated	Exposure to direct sunlight or UV light during treatment and for two weeks after discontinuation.
Not Recommended	Women in the first or second trimester of pregnancy.
Not Recommended	Women who are breastfeeding.
Use with Caution	Patients with severe renal, hepatic, or cardiac impairment or a history of peptic ulceration.

These classifications indicate that use is strictly prohibited for patients under 15 years old and those who are or will be exposed to sunlight during the treatment period. Use during pregnancy and lactation is either contraindicated or not recommended, and conditional use is defined for patients with severe underlying organ impairment.

The interaction profile for Ketoplus Cataplasma is primarily defined by its administration route, which results in low systemic exposure of the active ingredient, Ketoprofen. Regulatory documentation states that systemic drug-drug interactions are unlikely because serum concentrations following topical administration are minimal. No specific systemic medicines are formally listed as interacting based on pharmacokinetic mechanisms such as CYP enzyme inhibition or induction.

Interactions with Medicinal Products and Application Conditions

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may increase the potential for class-related systemic adverse effects due to an additive pharmacodynamic load. Procedural constraints on administration are necessary to manage exposure. The product must not be used with occlusive dressings, as this application condition can increase the systemic absorption of Ketoprofen.

Environmental and Topical Substance Restrictions

To avoid a photodynamic interaction risk, treated skin areas must be rigorously protected from direct sunlight or UV light (solarium) during treatment and for two weeks following discontinuation. Immediate discontinuation of the cataplasma is required if any skin reaction develops after co-application of octocrylene-containing products, indicating a specific local photodynamic interaction potential.

Population-Specific Cautions

Caution is advised when using this product in patients with reduced cardiac, hepatic, or renal function. This is a necessary consideration because, even with minimal systemic exposure, isolated cases of systemic adverse reactions, such as renal affections, have been reported in these specific populations.

How Ketoplus Cataplasma Works

Ketoprofen's mechanism involves modulation of inflammatory signaling at the molecular level.

Molecular Targeting of the COX Enzyme System

The active compound, Ketoprofen, exerts its action through the precise, non-selective inhibition of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This mechanism is fundamental because these enzymes are responsible for initiating the Arachidonic Acid Cascade, a critical pathway responsible for the biosynthesis of pro-inflammatory mediators and nociceptive sensitizers. By blocking the enzymes, the medicine directly interferes with this foundational molecular process.

⬇️ Suppression of Prostaglandin Synthesis and Nociception

This upstream enzyme blockade triggers a subsequent cascade where the local production and release of Prostaglandins, particularly the pain-sensitizing mediator PGE2, are consequentially reduced. The resulting drop in PGE2 concentration results in decreased chemical excitation and sensitization of peripheral nociceptors (sensory nerve endings). This biological sequence promotes an altered state within peripheral signaling pathways, which modifies the local physiological response.

Focused Peripheral Action via Cataplasma Delivery

The Cataplasma form dictates the drug's concentrated mechanism, establishing a high and sustained concentration gradient of Ketoprofen directly within the underlying soft tissues. This delivery method achieves and maintains a high local concentration of inhibitor, providing a focused peripheral action that is constrained only by the skin's barrier, the stratum corneum, and the depth of the target structure.

How to Use Ketoplus Cataplasma

Ketoplus Cataplasma is designed for topical administration, meaning it is applied directly to the skin. Standard protocols for its use define the application route, dosing schedule, and specific conditions necessary for proper administration.

---

Administration Scope

Entity	Instruction / Rule
Route of administration	Topical (or Cutaneous) use only.
Dosing schedule (Adults)	One (1) Cataplasma patch applied to the affected area.
Frequency	Applied twice daily (typically a 12-hour interval).
Age-group rule	Not recommended for use in children under 15 years.

---

The standard regimen involves applying one patch twice daily to a clean, dry, non-irritated skin surface. This medicine is intended strictly for short-term treatment and should be limited to the shortest duration necessary to relieve symptoms.

Application Requirements and Constraints

The following procedural constraints are associated with administration:

• Skin Condition: The patch must not be applied to open wounds, lesions, rashes, or mucosal surfaces.
• Covering: The patch must not be covered with an occlusive (airtight) dressing or bandage.
• Sun Exposure: Exposure of the treated area to direct sunlight or UV light (including tanning beds) must be strictly avoided during use and for up to two weeks following the treatment's discontinuation due to potential photosensitivity.

This structured application process ensures the administration adheres to the established requirements for this topical plaster.

Ketoplus Cataplasma: Overview of Studies

---

Research on Acute Localized Pain and Inflammation

Research has examined the patch in short-term, randomized controlled trials (RCTs) involving adult outpatients who had experienced mild to moderate injuries, such as sprains and strains. These studies monitored patient-reported outcomes related to physical discomfort over the initial treatment period. Trials reported patterns showing differences in the measured pain scores when comparing the active cataplasma to a placebo plaster. The evidence base describes patterns related to how symptoms evolved during the immediate recovery phase from a recent injury, although follow-up durations were typically limited to 7 to 14 days.

---

Research on Chronic Localized Conditions: Osteoarthritis

Intermediate-term trials, lasting six to twelve weeks, have evaluated the topical medicine for symptoms of chronic conditions, primarily osteoarthritis of the knee and small joints. These studies included adult patients and monitored outcomes reflecting daily functioning and activity level. Findings reported observations related to standardized pain and function scores when comparing the topical patch to other therapeutic approaches. The research is largely focused on superficial joints, and long-term effects are not fully established beyond the 12-week study period.

---

Study Populations and Research Gaps

The core research population across the clinical trials was primarily adult patients aged 18 to 75 with localized, uncomplicated conditions. Data for certain subgroups remain insufficient; for instance, there are limited published studies specifically examining the differences in outcomes for patients defined by complex comorbid conditions. Furthermore, evidence for treating conditions in deep-seated joints or for widespread functional limitations is not generally available, as the focus of the research remains on localized use.

Common questions about Ketoplus Cataplasma (FAQ)

Q: Is Ketoplus Cataplasma the same thing as a regular adhesive patch?

A: The official documentation describes the Cataplasma as a specialized medicinal plaster. Its unique identity is rooted in its dosage form, which uses a semi-solid hydrogel matrix to hold the medication. This design differs from regular adhesive patches, which are generally used only for basic wound coverage or protection.

Q: Why is this medicine used specifically for joint and muscle issues?

A: The cataplasma form is designed to provide a focused peripheral action of the medication. It achieves a high local concentration of the active ingredient directly within the underlying soft tissues. This mechanism explains why it is purposed for localized joint and muscle discomfort, as noted in official sources.

Q: How is the cataplasma form of Ketoplus different from a pill or gel for the same condition?

A: A key difference noted in regulatory pharmacokinetics is that topical application results in minimal systemic exposure of the active ingredient compared to taking a pill. This allows the medicine to be used for local relief, potentially with a lower likelihood of systemic side effects.

Q: Does Ketoplus Cataplasma contain any type of steroid component?

A: The active component of this medicine is Ketoprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official product identity documents confirm that the drug formulation does not include any steroid component.

Q: Why is the cataplasma formulation preferred over other delivery methods?

A: Official information indicates that the cataplasma system is designed to achieve a high local concentration of the drug at the site of discomfort. By delivering the medication through the skin, it minimizes the amount that enters the bloodstream, which contributes to a profile of low systemic exposure.

Q: Can I cut the Ketoplus Cataplasma into smaller pieces to fit a smaller area?

A: Regulatory information for similar products generally describes applying the patch as a whole unit. This is because cutting the Cataplasma may potentially affect the integrity of the drug release system and reduce the overall effectiveness of the application.

Q: Does bathing, showering, or swimming affect the absorption of the medicine?

A: Labeling describes applying the cataplasma to skin that is clean and dry to ensure proper adherence and absorption. While official documents do not explicitly detail constraints for bathing or swimming, the effectiveness of topical medicines may be affected by excessive moisture.

Q: What should be done if the cataplasma is accidentally left on for too long?

A: The recommended application frequency is precisely defined, often at a 12-hour interval. Official labeling notes that exceeding the recommended application duration may increase drug exposure, which is advised against.

Q: Is there a risk of developing a localized skin infection from the cataplasma itself?

A: The official eligibility scope states that the cataplasma is contraindicated for use on already infected, broken, or wounded skin. The most commonly documented skin-related side effects are primarily irritation or allergy-based, such as eczema or erythema.

Q: Can I get a headache or feel dizzy from using the Ketoplus Cataplasma?

A: Because the localized topical application results in minimal systemic absorption, common systemic side effects like headache or dizziness are considered unlikely. However, regulatory information notes that these effects are potential systemic side effects of NSAIDs, which could occur rarely if absorption increases.

Q: What are the possible signs that too much medicine is being absorbed into the body?

A: Isolated cases of systemic adverse reactions have been reported, which may indicate elevated systemic absorption. These rare events include renal affections (kidney-related issues) and severe systemic hypersensitivity reactions.

Q: Is Ketoplus Cataplasma considered a non-drowsy medication?

A: Systemic side effects such as drowsiness are generally associated with the oral forms of NSAIDs. Due to the very low systemic absorption rate of the topical cataplasma, the likelihood of this effect occurring is considered minimal.

Q: Is it safe to consume alcohol while using Ketoplus Cataplasma?

A: Although systemic absorption is minimal, the active ingredient is an NSAID. Regulatory information for the NSAID class indicates that the concomitant use of alcohol and NSAIDs is associated with an increased potential risk of gastrointestinal bleeding.

Q: Why does the list of eligibility exclusions (contraindications) seem so long for a topical medicine?

A: The extensive list is necessary because the medicine is a Nonsteroidal Anti-inflammatory Drug (NSAID). Even with low systemic exposure, it requires regulatory warnings related to the known NSAID class effects, such as potential cardiac and renal risks. Specific warnings for topical use, such as the risk of photosensitivity, also contribute to the length of the list.

Q: Does this medicine have abuse potential or is it addictive?

A: The active ingredient, Ketoprofen, is classified as an NSAID. Regulatory information does not identify Ketoprofen as a substance with known abuse potential or a risk of physical addiction.

Q: Is a slight redness or irritation on the skin after removing the cataplasma considered a normal side effect?

A: The most common documented local side effects, classified as Uncommon (occurring in ge1/1,000 to <1/100 patients), include erythema (redness) and pruritus (itching) at the application site. These are officially noted reactions to the product.

Q: How often does a systemic side effect occur with this type of patch medicine?

A: Regulatory documentation states that systemic adverse reactions are considered unlikely. This is because the serum concentrations following topical application are minimal—roughly 5% of the level obtained after an oral dose—limiting the potential for systemic effects.

Q: Can using Ketoplus Cataplasma long-term lead to thinning or discoloration of the skin?

A: Official instructions state that the medicine is intended strictly for short-term treatment. Long-term use is associated in regulatory documents with the risk of local skin sensitisation (hypersensitivity) and contact dermatitis. Skin thinning is not a commonly listed reaction for this topical form.

Q: Does the medicine from the cataplasma absorb into the body beyond the application site?

A: Yes, the active ingredient is absorbed beyond the application site and into the systemic circulation. However, this absorption is significantly constrained by the skin barrier. Regulatory documents note that this results in low systemic exposure of the drug.

Q: Can using too many cataplasmas at once be harmful?

A: The recommended administration involves the application of only one (1) Cataplasma patch at a time. Regulatory information states that exceeding the recommended amount may increase the potential for class-related systemic adverse effects due to an additive pharmacodynamic load.

Q: Does the cataplasma formulation interact with any commonly used oral medications?

A: Regulatory documentation indicates that systemic drug-drug interactions are unlikely due to the minimal serum concentrations achieved with the topical form. However, co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the potential for systemic class-related adverse effects.

Q: Are there any known interactions between the cataplasma and other topical products like moisturizers?

A: Official safety documents describe that discontinuation is necessary if a skin reaction develops after co-application of octocrylene-containing products. This indicates a specific local photodynamic interaction potential with that ingredient.

Q: Can elderly patients use Ketoplus Cataplasma without special considerations?

A: Official safety patterns indicate that elderly patients are considered more susceptible to NSAID adverse events, even with topical use. Regulatory documents describe that the product is intended to be used with caution in this specific population.

How to Store and Dispose of Ketoplus Cataplasma

The storage and disposal of this ketoprofen medicinal plaster are governed by official regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with temperatures not exceeding 30 C.
Protection	Keep the product in the original sealed package, protected from moisture.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Protocol

Unused or expired Cataplasma must be disposed of safely. Do not keep outdated medicine. Users must consult a pharmacist or healthcare professional for guidance on the correct method for disposal, ensuring that the medicine is not thrown into household trash or wastewater.